NPR/Marketplace story on price/value and PCSK9 approvals:
“The price can’t be considered a stagnant proposition. It needs to be a vibrant, living thing,” said FDA consultant Peter Pitts.
Boston Globe (Ed Silverman) on things to watch (per pharma) in 2016:
A key unknown, however, is whether drug makers will become more transparent about their pricing strategies when negotiating with these payers. This is a “very important” part of determining value for patients, noted Peter Pitts, a former Food and Drug Administration official who now heads the Center for Medicine in the Public Interest.
Happy New Year
